AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29670279
Drug: F-652 (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-652 (IV infusion at 2.0, 10, 30, and 45 µg/kg)
Trial: 29670279
Drug: F-652 (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-652 (IV infusion)
Trial: 29670279
Drug: F-652 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-652 (45 µg/kg, IV)
Trial: 23684013
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous blood (ABI) alone
Trial: 23684013
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous blood (ABI) and intramaxillary fixation (IMF) for 4 weeks
Trial: 21063429
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (SF: 14.1 g/l protein, 662 kcal/l)
Trial: 21063429
Drug: Experimental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formula (EF: 12.8 g/l protein, 662 kcal/l)
Trial: 19302900
Drug: Risedronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 100 mg/mo
Trial: 19302900
Drug: Risedronate 150
RxNorm normalized name: risedronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 150 mg/mo
Trial: 19302900
Drug: Risedronate 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 200 mg/mo
Trial: 19302900
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/d (active control)
Trial: 19302900
Drug: Risedronate 150
RxNorm normalized name: risedronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 150 mg/mo and 200 mg/mo
Trial: 12911187
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/d
Trial: 10049522
Drug: Interferons (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferons (IFN) beta and gamma in combination with hormonotherapy (Megace or Tamoxifen)
Trial: 8281698
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus anticoagulation (aspirin 162.5 mg daily plus heparin followed by aspirin 162.5 mg daily plus warfarin)
Trial: 8281698
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (162.5 mg daily)
Trial: 8281698
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (aspirin plus anticoagulation)
Trial: 30502489
Drug: Vaccine strain
RxNorm normalized name: Rubella virus (vaccine strain RA27/3) live antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine strain (mumps vaccine)
Trial: 30502489
Drug: Vaccine strain
RxNorm normalized name: Rubella virus (vaccine strain RA27/3) live antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine strain vs Wild-type virus
Trial: 27402475
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (250,000 IU, one-time oral dose)
Trial: 25967093
Drug: Intensified work-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified work-related rehabilitation aftercare program (including functional capacity training, psychosocial groups, social counseling, relaxation training, and exercise therapy)
Trial: 25967093
Drug: Standard intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensified rehabilitation aftercare (consisting of only exercise therapy)
Trial: 25549015
Drug: Ginger (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (as a drug)
Trial: 15202299
Drug: Cytotoxic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic and glucocorticoid therapy
Trial: 15202299
Drug: Before therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before therapy
Trial: 8106625
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg/day)
Trial: 8302150
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine in 10 mL normal saline with epinephrine 0.1 mg (1:100,000, 10 micrograms/mL)
Trial: 8302150
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine in 10 mL normal saline without epinephrine
Trial: 3731824
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg sustained-release oxprenolol once daily
Trial: 3731824
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide/50 mg triamterene once daily
Trial: 3731824
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 160 mg sustained-release oxprenolol and 25 mg hydrochlorothiazide/50 mg triamterene once daily
Trial: 3731824
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg sustained-release oxprenolol alone
Trial: 3731824
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide/50 mg triamterene alone
Trial: 2534412
Drug: Hydrochlorothiazide treatment
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide treatment
Trial: 28815997
Drug: Twice-daily sustained-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily sustained-release (SR) paracetamol (2 × 1000 mg twice daily)
Trial: 22811926
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (1 capsule/day) for 6 months after a wash-out period
Trial: 22811926
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (1 capsule/day)
Trial: 18489612
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg for 1 week
Trial: 18489612
Drug: Atropine (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (nonselective muscarinic antagonist)
Trial: 2386447
Drug: scopolamine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (1.0 mg)
Trial: 7389389
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg 3-times daily
Trial: 7389389
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg 3-times daily
Trial: 31775843
Drug: SHGBZK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHGBZK treatment
Trial: 24599676
Drug: Balneotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy plus physical therapy (n=37)
Trial: 24599676
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy alone (n=44)
Trial: 17559990
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Trial: 17559990
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Trial: 17559990
Drug: Combined IM
RxNorm normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined IM and IN administration of trivalent inactivated influenza vaccine
Trial: 3655856
Drug: CAF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF chemotherapy (cyclophosphamide + doxorubicin + 5‐fluorouracil [5‐FU])
Trial: 3655856
Drug: CAF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF chemotherapy (for ER+ patients)
Trial: 3655856
Drug: CAF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF chemotherapy (for ER- patients)
Trial: 29023249
Drug: 1-Hz repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Trial: 29023249
Drug: Sham 1-Hz
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Trial: 24172209
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER (40 to 120 mg/d)
Trial: 20155988
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day (monotherapy)
Trial: 20155988
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day with pravastatin 10 mg/day
Trial: 20155988
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day with rosuvastatin 2.5 mg/day
Trial: 20155988
Drug: ezetimibe (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (both monotherapy and combination therapy)
Trial: 11919665
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg on days 1-8, 100 mg on days 9-15)
Trial: 11919665
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg on days 1-8, 40 mg on days 9-15)
Trial: 10344359
Drug: Hb concentration
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hb concentration of 14 g/dl ([Hb]14)
Trial: 10344359
Drug: Hb concentration
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hb concentration of 10 g/dl ([Hb]10)
Trial: 2035006
Drug: Salt loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt loading (+6.1 +/- 2.8 g NaCl/d = 105 +/- 48 mmol Na)
Trial: 2035006
Drug: Loading with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading with sodium citrate in equimolar concentrations (+140 +/- 40 ml Shohl's solution = 120 +/- 34 mmol Na)
Trial: 7237927
Drug: Low cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low cholesterol fat-modified diet (mean 200 mg/day, polyunsaturated/saturated fat ratio of 1.0, 43% of total energy from fat)
Trial: 31779672
Drug: Cryo-RDN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryo-RDN treatment
Trial: 31779672
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (renal angiography alone)
Trial: 22077869
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 400 mg
Trial: 9594474
Drug: Nonvital pulp
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvital pulp treatment
Trial: 7983882
Drug: Leukocyte-depleted terminal
RxNorm normalized name: Terminator
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte-depleted terminal cardioplegic solution (n = 10)
Trial: 7983882
Drug: Terminal cardioplegic
RxNorm normalized name: Terminator
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terminal cardioplegic solution (n = 10)
Trial: 29806665
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm long × 4 mm wide implants
Trial: 29806665
Drug: Implants of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants of at least 10 mm long
Trial: 29065426
Drug: FOLFOX-4 or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-4 or XELOX adjuvant chemotherapy
Trial: 17914655
Drug: argon plasma
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: argon plasma coagulation plus imiquimod cream
Trial: 17914655
Drug: HIV-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-positive patients with combination therapy
Trial: 17914655
Drug: HIV-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-positive patients with monotherapy
Trial: 14681347
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (SJW) 300 mg three times a day for 15 days
Trial: 14681347
Drug: Theophylline 400
RxNorm normalized name: theophylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 400 mg single oral dose
Trial: 11010695
Drug: Gender, limitations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender, limitations in daily living activities, dementia, and utilization of services
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 50 mg
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 100 mg
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 200 mg
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 300 mg
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 500 mg
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 200 mg after a meal
Trial: 9403274
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil (ME1207) 200 mg every 12 h for 7 days
Trial: 3548954
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (chronic phase)
Trial: 3548954
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (acute phase)
Trial: 3548954
Drug: Intramuscular placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placebo (acute phase)
Trial: 30561029
Drug: Psyllium group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium group (Mucilin SF 15.2 g/L added to Blendera)
Trial: 15082421
Drug: Palm oil
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oil infusion
Trial: 15082421
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil infusion
Trial: 10453752
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (DSCG non-treated patients)
Trial: 7884019
Drug: Doxepin 150
RxNorm normalized name: doxepin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 150 mg per day
Trial: 3067744
Drug: Carteolol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 2% twice daily
Trial: 18795647
Drug: CPC/ZG gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC/ZG gel (0.10% cetylpyridinium chloride and 0.592% zinc gluconate)
Trial: 18795647
Drug: Control gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control gel (0% CPC and 0.592% ZG)
Trial: 16636029
Drug: Doxapram hydrochloride
RxNorm normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxapram hydrochloride 1 mg.kg(‐1) iv
Trial: 12100930
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% lidocaine gel intrarectally
Trial: 12100930
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 1% lidocaine solution periprostatic injection
Trial: 2328553
Drug: WEB-2086 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEB-2086 (40 mg)
Trial: 6931307
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy containing MeCCNU
Trial: 30985546
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral load >10,000 copies/mL
Trial: 30985546
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral load <1000 copies/mL
Trial: 30985546
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral load 1000.1-10,000 copies/mL
Trial: 23896581
Drug: 2010-2011 seasonal
RxNorm normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by GlaxoSmithKline
Trial: 23896581
Drug: 2010-2011 seasonal
RxNorm normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sanofi Pasteur
Trial: 23896581
Drug: 2010-2011 seasonal
RxNorm normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sinovac Biotech
Trial: 23896581
Drug: 2010-2011 seasonal
RxNorm normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV)
Trial: 19706087
Drug: Combination bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination bathing and emollient application regimens
Trial: 25687540
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin application
Trial: 25990305
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of MRA therapy (potassium canrenoate 200 mg) followed by oral spironolactone 50 mg once daily for 3 months
Trial: 15552355
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of items for selection
Trial: 9371930
Drug: Optic neuritis
RxNorm normalized name: Opti-Nail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optic neuritis treatment
Trial: 1287831
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit with 50% reduction of systemic heparin bolus
Trial: 1287831
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard heparin treatment)
Trial: 12281505
Drug: hCG injections
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injections (250 IU/day i.m.) for 21 days in OC users
Trial: 12281505
Drug: hCG injections
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injections (250 IU/day i.m.)
Trial: 29097325
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg dezocine
Trial: 29097325
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg dezocine
Trial: 29097325
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg dezocine
Trial: 29097325
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.1 mg/kg)
Trial: 24057149
Drug: Intravenous amantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amantadine